Clinical Trial Update: A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 single-blind trial evaluating safety, tolerability and exploratory efficacy of 8.0 mg ASM8 inhaled daily for 14 days in severe asthma was withdrawn by…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• ASM8 inhaled (ASM8)

Snippet

Sponsor: Syntara | Conditions: Asthma | Phase 2 | Status: WITHDRAWN